ezn-296
Nucleic acidexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2007 (NCT00466583)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
HIF1A agonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ezn-296
- ezn2968
- ezn 2968
- ezn-2968
- ezn-2968
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01120288 | Phase 1 | Apr 29, 2010 | National Cancer Institute (NCI) |
| NCT00466583 | Phase 1 | Mar 1, 2007 | Duke University, Enzon, Joe Arrington Cancer Center, Temple University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Enzon | For profit | 1 | 1 | 1 | 2007 |
| Joe Arrington Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2007 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2010 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 2007 |
5 organizations
Page 1 / 1